Palo Alto, Calif. – August 18, 2021 – Endpoint Health, an integrated precision therapeutics company dedicated to addressing urgent needs in immune-driven critical and chronic illnesses, today announced biopharma veteran Kirsten Detrick has joined the company as Chief Commercial Officer.
“With a proven track record of success and more than 25 years of commercial expertise in the biopharmaceutical industry, Kirsten assumes a critical role in our growing organization,” said Jason Springs, co-founder and Chief Executive Officer at Endpoint Health. “We look forward to the strategic insights that she will bring to Endpoint Health as we progress our business model to ensure that every patient receives a therapy personalized to their biology and clinical needs.”
Detrick joins Endpoint Health from Takeda, where she variously served as Vice President and Therapy Area Commercial Leader for the Global Gastrointestinal franchise; General Manager of Austria; and Head of Takeda’s Multi-Country Organization in Central and Eastern Europe, which added the Czech Republic and Slovakia to her portfolio. Prior to Takeda, she held a variety of leadership roles at other leading biopharma companies, including Amgen and Bristol-Myers Squibb.
Throughout her career, Detrick has leveraged foundational consumer product marketing and global commercialization expertise to launch and/or lead numerous products in immune-mediated categories, oncology and rare as well as specialty disease states. Detrick holds an MBA from The Tuck School of Business at Dartmouth College and a B.A. in Chemistry from Middlebury College.
“There is no better time to be joining Endpoint Health as we accelerate progress towards developing and commercializing precision therapeutics and therapy-guiding tests in a variety of complex disease states,” said Detrick. “I look forward to working with this high-caliber team to capitalize on the promise of personalized medicine for patients who will benefit from our ground-breaking approach.”
About Endpoint Health
Endpoint Health is a precision therapeutics company dedicated to addressing urgent needs in immune-driven critical and chronic illnesses by delivering therapies that are personalized to each patient’s biology. We combine therapeutics, diagnostics and AI into an integrated platform designed to bring targeted therapies to patients with inflammatory illnesses, such as acute respiratory distress syndrome (ARDS), sepsis and rheumatoid arthritis. Our vision is a world in which all patients have effective, personalized treatment, because therapies are targeted to the right patient at the right time. For more information, visit www.endpoint.health.